Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis
出版年份 2018 全文链接
标题
Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis
作者
关键词
NASH, CDAA, Cholesterol, Elafibranor, OCA, Fibrosis
出版物
DIGESTIVE DISEASES AND SCIENCES
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-12-03
DOI
10.1007/s10620-018-5395-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis
- (2018) Manuel Baader et al. BRITISH JOURNAL OF PHARMACOLOGY
- Lipotoxicity and the gut-liver axis in NASH pathogenesis
- (2018) Fabio Marra et al. JOURNAL OF HEPATOLOGY
- Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential
- (2018) Pierre Bedossa LIVER INTERNATIONAL
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
- (2018) Kirstine S Tølbøl et al. WORLD JOURNAL OF GASTROENTEROLOGY
- INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
- (2018) Jonathan D Roth et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet
- (2017) Ayae Ikawa-Yoshida et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- Pathology of non-alcoholic fatty liver disease
- (2017) Pierre Bedossa LIVER INTERNATIONAL
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- The epidemiology of non-alcoholic fatty liver disease
- (2017) Stefano Bellentani LIVER INTERNATIONAL
- Induction of Steatohepatitis (NASH) with Insulin Resistance in Wild-type B6 Mice by a Western-type Diet Containing Soybean Oil and Cholesterol
- (2017) Janin Henkel et al. MOLECULAR MEDICINE
- Targeting nuclear receptors for the treatment of fatty liver disease
- (2017) Naoki Tanaka et al. PHARMACOLOGY & THERAPEUTICS
- Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging
- (2017) Seong Min Kim et al. Oncotarget
- Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease
- (2017) Wenjing Luo et al. Scientific Reports
- Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
- (2017) Hani Jouihan et al. Molecular Metabolism
- Non-alcoholic fatty liver disease in 2016
- (2016) S.A. Townsend et al. BRITISH MEDICAL BULLETIN
- Emerging therapeutic targets for the treatment of hepatic fibrosis
- (2016) Paolo Fagone et al. DRUG DISCOVERY TODAY
- Obeticholic Acid: First Global Approval
- (2016) A. Markham et al. DRUGS
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge
- (2016) Yuichiro Amano et al. HEPATOLOGY RESEARCH
- A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
- (2016) Amon Asgharpour et al. JOURNAL OF HEPATOLOGY
- Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
- (2016) Giovanni Musso et al. NATURE REVIEWS DRUG DISCOVERY
- Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice
- (2016) Fahrettin Haczeyni et al. Obesity
- The Role of Cholesterol in the Pathogenesis of NASH
- (2016) George N. Ioannou TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Kupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and Inflammation
- (2016) D. T. Reid et al. PLoS One
- The impact of PPARα activation on whole genome gene expression in human precision cut liver slices
- (2015) Aafke W.F. Janssen et al. BMC GENOMICS
- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
- (2015) Yuka Hayashizaki-Someya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Bile acids: emerging role in management of liver diseases
- (2015) Amon Asgharpour et al. Hepatology International
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease
- (2015) Hyun Jung Lee WORLD JOURNAL OF GASTROENTEROLOGY
- Nonalcoholic fatty liver disease
- (2015) Elizabeth M. Brunt et al. Nature Reviews Disease Primers
- NLRP3 inflammasome activation is required for fibrosis development in NAFLD
- (2014) Alexander Wree et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Overactivation of Intestinal SREBP2 in Mice Increases Serum Cholesterol
- (2014) Ke Ma et al. PLoS One
- HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
- (2014) Samuele De Minicis et al. PLoS One
- Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology
- (2014) Wen Liang et al. PLoS One
- Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
- (2013) Jason R. Clapper et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease
- (2013) Victoria L. Gadd et al. HEPATOLOGY
- Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model
- (2013) Yosuke Aihara et al. HEPATOLOGY RESEARCH
- An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis
- (2013) Masahiko Matsumoto et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis
- (2013) Hitoshi Yoshiji et al. JOURNAL OF GASTROENTEROLOGY
- NAFLD, NASH and liver cancer
- (2013) Gregory A. Michelotti et al. Nature Reviews Gastroenterology & Hepatology
- Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
- (2012) James L. Trevaskis et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
- (2012) Kouichi Miura et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Liver Transplantation for Nonalcoholic Steatohepatitis
- (2012) Vatche G. Agopian et al. ANNALS OF SURGERY
- Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis
- (2012) Yosui Tamaki et al. JOURNAL OF GASTROENTEROLOGY
- Roles of PPARs in NAFLD: Potential therapeutic targets
- (2011) Anne Tailleux et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation
- (2011) Christian L. Roth et al. HEPATOLOGY
- Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective
- (2011) Carolin Lackner Expert Review of Gastroenterology & Hepatology
- Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation
- (2010) Massimo Collino et al. BRITISH JOURNAL OF PHARMACOLOGY
- Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
- (2010) Kouichi Miura et al. GASTROENTEROLOGY
- Kupffer cells in non-alcoholic fatty liver disease: The emerging view
- (2009) György Baffy JOURNAL OF HEPATOLOGY
- Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
- (2009) Songwen Zhang et al. JOURNAL OF HEPATOLOGY
- Immunotherapy for nonalcoholic steatohepatitis using themultiple cytokine production modulator Y-40138
- (2009) Tatsuhiro Tsujimoto et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease
- (2008) K Fujita et al. GUT
- Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet
- (2008) Mary E. Rinella et al. JOURNAL OF LIPID RESEARCH
- Innate immune reactivity of the liver in rats fed a cholinedeficient L-amino-acid-defined diet
- (2008) Hideto Kawaratani et al. WORLD JOURNAL OF GASTROENTEROLOGY
- PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators
- (2007) Frank J. Gonzalez et al. TOXICOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started